Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug
Lenacapavir is already approved for treatment of HIV,
and is under regulatory review for prevention, but it has a price tag of
$42,250. As a result, ... |
Updates & Legacy — Stigmabase is a Canadian Non-Governmental & Nonprofit Initiative. Our mission is to inform about stigma around the world and make the data collected accessible for researchers. Stigmabase is very attentive to misinformation and lists only reliable sources. — The marginalization of individuals or categories of individuals is a too common phenomenon. Millions of people are facing this problem around the world and many complex factors are involved.